United Therapeutics (NASDAQ:UTHR) COO Sells $7,127,932.50 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 14,625 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $487.38, for a total transaction of $7,127,932.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total transaction of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total value of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.91, for a total value of $10,797,975.00.
• On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $473.66, for a total value of $10,657,350.00.
• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total transaction of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $429.25, for a total transaction of $9,658,125.00.

United Therapeutics Stock Up 0.2%

Shares of UTHR traded up $0.98 during mid-day trading on Wednesday, hitting $503.69. 302,934 shares of the company’s stock were exchanged, compared to its average volume of 437,984. The stock has a market cap of $21.69 billion, a price-to-earnings ratio of 19.09, a P/E/G ratio of 4.71 and a beta of 0.84. The firm has a fifty day moving average of $481.47 and a two-hundred day moving average of $398.76. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the company posted $6.39 earnings per share. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. Royal Bank Of Canada raised their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. UBS Group boosted their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. Finally, Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Clearstead Advisors LLC boosted its stake in shares of United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 23 shares in the last quarter. Bessemer Group Inc. raised its holdings in United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the last quarter. Archer Investment Corp lifted its position in United Therapeutics by 9.5% during the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 31 shares during the period. F m Investments LLC boosted its stake in shares of United Therapeutics by 1.3% in the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC grew its position in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after buying an additional 35 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.